Shopping Cart 0
Cart Subtotal
USD 0

OPKO Health Inc (OPK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company's product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers its diagonostics and therapeutics that are used in the treatment of chronic kidney disease, obesity, asthma, chronic obstructive pulmonary disease (COPD), cancer and chemotherapy-induced nausea and vomiting, among others. It also offers neutraceuticals and veterinary products.The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deal Details 18

Venture Financing 18

Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20

Partnerships 21

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23

Licensing Agreements 24

Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27

Opko Health Enters into Licensing Agreement with Pfizer 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30

OPKO Health Enters Into Licensing Agreement With ChromaDex 31

Opko Health Enters into Licensing Agreement with DSG 32

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33

Opko Health Enters Into Licensing Agreement With Pharmsynthez 35

Opko Health Enters Into Licensing Agreement For Ranibizumab 37

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39

Equity Offering 40

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50

Transition Therapeutics Raises USD17 Million in Private Placement of Units 51

BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53

Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54

Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56

Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57

RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58

Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59

ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61

Debt Offering 63

OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63

Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64

Asset Transactions 66

RXi Pharma Acquires RNAi-Related Assets from Opko Health 66

Acquisition 68

OPKO Health Acquires 5.11% Stake in RXi Pharma 68

OPKO Health Acquires Transition Therapeutics for USD60 Million 69

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70

Opko Health Acquires Bio-Reference Labs 71

OPKO Health Acquires EirGen Pharma for USD135 Million 73

Opko Health Acquires Inspiro Medical 74

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75

Opko Health Completes Acquisition Of Laboratorio Arama 76

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79

BioReference Labs Acquires Hunter Labs 80

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82

Opko Health Completes Acquisition Of Silcon Comercio 84

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85

Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86

OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88

OPKO Health Inc-Key Competitors 89

OPKO Health Inc-Key Employees 90

OPKO Health Inc-Locations And Subsidiaries 91

Head Office 91

Other Locations & Subsidiaries 91

Recent Developments 94

Financial Announcements 94

Aug 07, 2018: Opko Health announces second quarter 2018 financial results 94

May 08, 2018: OPKO Health Announces First Quarter 2018 Financial Results 95

Mar 01, 2018: OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results 97

Nov 08, 2017: OPKO Health Reports 2017 Third Quarter Highlights and Financial Results 99

Aug 08, 2017: OPKO Health Reports Second Quarter 2017 Business and Financial Results 100

May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 102

Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 103

Corporate Communications 105

Jan 26, 2018: OPKO Health Announces Resignation Of Gregory Henderson As President Of BioReference Laboratories 105

Sep 06, 2017: Sandra Cole Appointed Vice President and Chief Compliance Officer for OPKO's BioReference Laboratories 106

Aug 21, 2017: Update: Victoria Laughman Named Executive Vice President of Sales for OPKO's BioReference Laboratories 107

Feb 07, 2017: OPKO Health names new chief commercial officer for renal division 108

Legal and Regulatory 109

Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 109

Government and Public Interest 110

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD 110

Product Approvals 111

Mar 22, 2017: OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 111

Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 112

Clinical Trials 113

Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy 113

Appendix 114

Methodology 114

About GlobalData 114

Contact Us 114

Disclaimer 114


List Of Figure

List of Figures

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

OPKO Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23

Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27

Opko Health Enters into Licensing Agreement with Pfizer 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30

OPKO Health Enters Into Licensing Agreement With ChromaDex 31

Opko Health Enters into Licensing Agreement with DSG 32

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33

Opko Health Enters Into Licensing Agreement With Pharmsynthez 35

Opko Health Enters Into Licensing Agreement For Ranibizumab 37

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50

Transition Therapeutics Raises USD17 Million in Private Placement of Units 51

BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53

Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54

Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56

Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57

RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58

Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59

ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61

OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63

Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64

RXi Pharma Acquires RNAi-Related Assets from Opko Health 66

OPKO Health Acquires 5.11% Stake in RXi Pharma 68

OPKO Health Acquires Transition Therapeutics for USD60 Million 69

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70

Opko Health Acquires Bio-Reference Labs 71

OPKO Health Acquires EirGen Pharma for USD135 Million 73

Opko Health Acquires Inspiro Medical 74

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75

Opko Health Completes Acquisition Of Laboratorio Arama 76

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79

BioReference Labs Acquires Hunter Labs 80

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82

Opko Health Completes Acquisition Of Silcon Comercio 84

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85

Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86

OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88

OPKO Health Inc, Key Competitors 89

OPKO Health Inc, Key Employees 90

OPKO Health Inc, Other Locations 91

OPKO Health Inc, Subsidiaries 91

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

OPKO Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company's product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers its diagonostics and therapeutics that are used in the treatment of chronic kidney disease, obesity, asthma, chronic obstructive pulmonary disease (COPD), cancer and chemotherapy-induced nausea and vomiting, among others. It also offers neutraceuticals and veterinary products.The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deal Details 18

Venture Financing 18

Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20

Partnerships 21

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23

Licensing Agreements 24

Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27

Opko Health Enters into Licensing Agreement with Pfizer 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30

OPKO Health Enters Into Licensing Agreement With ChromaDex 31

Opko Health Enters into Licensing Agreement with DSG 32

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33

Opko Health Enters Into Licensing Agreement With Pharmsynthez 35

Opko Health Enters Into Licensing Agreement For Ranibizumab 37

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39

Equity Offering 40

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50

Transition Therapeutics Raises USD17 Million in Private Placement of Units 51

BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53

Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54

Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56

Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57

RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58

Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59

ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61

Debt Offering 63

OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63

Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64

Asset Transactions 66

RXi Pharma Acquires RNAi-Related Assets from Opko Health 66

Acquisition 68

OPKO Health Acquires 5.11% Stake in RXi Pharma 68

OPKO Health Acquires Transition Therapeutics for USD60 Million 69

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70

Opko Health Acquires Bio-Reference Labs 71

OPKO Health Acquires EirGen Pharma for USD135 Million 73

Opko Health Acquires Inspiro Medical 74

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75

Opko Health Completes Acquisition Of Laboratorio Arama 76

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79

BioReference Labs Acquires Hunter Labs 80

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82

Opko Health Completes Acquisition Of Silcon Comercio 84

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85

Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86

OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88

OPKO Health Inc-Key Competitors 89

OPKO Health Inc-Key Employees 90

OPKO Health Inc-Locations And Subsidiaries 91

Head Office 91

Other Locations & Subsidiaries 91

Recent Developments 94

Financial Announcements 94

Aug 07, 2018: Opko Health announces second quarter 2018 financial results 94

May 08, 2018: OPKO Health Announces First Quarter 2018 Financial Results 95

Mar 01, 2018: OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results 97

Nov 08, 2017: OPKO Health Reports 2017 Third Quarter Highlights and Financial Results 99

Aug 08, 2017: OPKO Health Reports Second Quarter 2017 Business and Financial Results 100

May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 102

Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 103

Corporate Communications 105

Jan 26, 2018: OPKO Health Announces Resignation Of Gregory Henderson As President Of BioReference Laboratories 105

Sep 06, 2017: Sandra Cole Appointed Vice President and Chief Compliance Officer for OPKO's BioReference Laboratories 106

Aug 21, 2017: Update: Victoria Laughman Named Executive Vice President of Sales for OPKO's BioReference Laboratories 107

Feb 07, 2017: OPKO Health names new chief commercial officer for renal division 108

Legal and Regulatory 109

Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 109

Government and Public Interest 110

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD 110

Product Approvals 111

Mar 22, 2017: OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 111

Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 112

Clinical Trials 113

Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy 113

Appendix 114

Methodology 114

About GlobalData 114

Contact Us 114

Disclaimer 114


List Of Figure

List of Figures

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

OPKO Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

OPKO Health Inc, Deals By Therapy Area, 2012 to YTD 2018 10

OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23

Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27

Opko Health Enters into Licensing Agreement with Pfizer 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30

OPKO Health Enters Into Licensing Agreement With ChromaDex 31

Opko Health Enters into Licensing Agreement with DSG 32

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33

Opko Health Enters Into Licensing Agreement With Pharmsynthez 35

Opko Health Enters Into Licensing Agreement For Ranibizumab 37

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50

Transition Therapeutics Raises USD17 Million in Private Placement of Units 51

BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53

Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54

Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56

Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57

RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58

Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59

ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61

OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63

Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64

RXi Pharma Acquires RNAi-Related Assets from Opko Health 66

OPKO Health Acquires 5.11% Stake in RXi Pharma 68

OPKO Health Acquires Transition Therapeutics for USD60 Million 69

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70

Opko Health Acquires Bio-Reference Labs 71

OPKO Health Acquires EirGen Pharma for USD135 Million 73

Opko Health Acquires Inspiro Medical 74

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75

Opko Health Completes Acquisition Of Laboratorio Arama 76

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79

BioReference Labs Acquires Hunter Labs 80

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82

Opko Health Completes Acquisition Of Silcon Comercio 84

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85

Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86

OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88

OPKO Health Inc, Key Competitors 89

OPKO Health Inc, Key Employees 90

OPKO Health Inc, Other Locations 91

OPKO Health Inc, Subsidiaries 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

OPKO Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.